Liquidia (NASDAQ:LQDA) Director Sells $4,047,000.00 in Stock

Liquidia Corporation (NASDAQ:LQDA) Director Stephen Bloch sold 50,000 shares of the stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $80.94, for a total value of $4,047,000.00. Following the transaction, the director directly owned 780,073 shares in the company, valued at approximately $63,139,108.62. This represents a 6.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Liquidia Stock Performance

Shares of LQDA traded down $1.76 during mid-day trading on Wednesday, hitting $79.47. The stock had a trading volume of 1,738,308 shares, compared to its average volume of 1,851,688. Liquidia Corporation has a fifty-two week low of $12.88 and a fifty-two week high of $82.96. The company has a quick ratio of 2.03, a current ratio of 2.22 and a debt-to-equity ratio of 1.18. The company has a market cap of $7.07 billion, a PE ratio of 567.68 and a beta of 0.55. The company’s fifty day simple moving average is $62.48 and its two-hundred day simple moving average is $46.03.

Liquidia (NASDAQ:LQDA) last posted its quarterly earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.11. The business had revenue of $132.87 million for the quarter, compared to analyst estimates of $119.44 million. Liquidia had a return on equity of 46.82% and a net margin of 7.74%.The firm’s quarterly revenue was up 4187.1% on a year-over-year basis. On average, equities analysts expect that Liquidia Corporation will post 3.02 earnings per share for the current year.

Institutional Trading of Liquidia

Several hedge funds have recently bought and sold shares of LQDA. Farallon Capital Management LLC grew its position in Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after purchasing an additional 4,326,876 shares during the last quarter. TCG Crossover Management LLC acquired a new stake in Liquidia in the 3rd quarter valued at approximately $38,887,000. MPM Bioimpact LLC raised its stake in Liquidia by 600.4% during the 4th quarter. MPM Bioimpact LLC now owns 1,400,869 shares of the company’s stock valued at $48,316,000 after acquiring an additional 1,200,869 shares in the last quarter. Voloridge Investment Management LLC bought a new stake in Liquidia during the 3rd quarter valued at $12,571,000. Finally, Apis Capital Advisors LLC acquired a new position in Liquidia during the 3rd quarter worth $9,569,000. 64.54% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

LQDA has been the subject of several research reports. Needham & Company LLC lifted their price target on shares of Liquidia from $54.00 to $70.00 and gave the company a “buy” rating in a report on Monday, May 11th. Jefferies Financial Group reiterated a “buy” rating and set a $60.00 price objective on shares of Liquidia in a research note on Monday, May 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Liquidia in a report on Tuesday, April 21st. Wall Street Zen downgraded Liquidia from a “strong-buy” rating to a “buy” rating in a research note on Saturday, June 27th. Finally, Zacks Research raised Liquidia from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 5th. Three research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $68.88.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).